These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 9079190)

  • 21. Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity.
    Neafsey P; Ginsberg G; Hattis D; Johns DO; Guyton KZ; Sonawane B
    J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):362-88. PubMed ID: 20183527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Some aspects of interindividual variations in the metabolism of xenobiotics.
    Tamási V; Vereczkey L; Falus A; Monostory K
    Inflamm Res; 2003 Aug; 52(8):322-33. PubMed ID: 14504670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
    Prandota J
    Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.
    Forrester LM; Henderson CJ; Glancey MJ; Back DJ; Park BK; Ball SE; Kitteringham NR; McLaren AW; Miles JS; Skett P
    Biochem J; 1992 Jan; 281 ( Pt 2)(Pt 2):359-68. PubMed ID: 1736885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
    Nebert DW; McKinnon RA; Puga A
    DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interpatient variability: genetic predisposition and other genetic factors.
    West WL; Knight EM; Pradhan S; Hinds TS
    J Clin Pharmacol; 1997 Jul; 37(7):635-48. PubMed ID: 9243358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytochrome P450 polymorphism: From evolution to clinical use.
    Ingelman-Sundberg M
    Adv Pharmacol; 2022; 95():393-416. PubMed ID: 35953162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes.
    Yamazaki H
    Chem Res Toxicol; 2017 Jan; 30(1):53-60. PubMed ID: 27750412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obstetric therapeutics-how pharmacogenetics may inform drug therapy for pregnant women in the future.
    Haas DM
    Obstet Gynecol Surv; 2013 Sep; 68(9):650-4. PubMed ID: 25102121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and phase II drug-metabolizing enzymes are expressed and heterogeneously distributed in the biliary epithelium.
    Lakehal F; Wendum D; Barbu V; Becquemont L; Poupon R; Balladur P; Hannoun L; Ballet F; Beaune PH; Housset C
    Hepatology; 1999 Dec; 30(6):1498-506. PubMed ID: 10573530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochrome p450 part 2: what nurses need to know about the cytochrome p450 family systems.
    Krau SD
    Nurs Clin North Am; 2013 Dec; 48(4):681-96. PubMed ID: 24295195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug metabolizing enzymes related to laboratory medicine: cytochromes P-450 and UDP-glucuronosyltransferases.
    Batt AM; Magdalou J; Vincent-Viry M; Ouzzine M; Fournel-Gigleux S; Galteau MM; Siest G
    Clin Chim Acta; 1994 May; 226(2):171-90. PubMed ID: 7923812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytochromes P450 in the bioactivation of chemicals.
    Ioannides C; Lewis DF
    Curr Top Med Chem; 2004; 4(16):1767-88. PubMed ID: 15579107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular modeling of cytochrome P450 and drug metabolism.
    Wang JF; Chou KC
    Curr Drug Metab; 2010 May; 11(4):342-6. PubMed ID: 20446905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic polymorphism of CYP2A6 in the German population.
    Bourian M; Gullstén H; Legrum W
    Toxicology; 2000 Apr; 144(1-3):129-37. PubMed ID: 10781880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.
    Rushmore TH; Kong AN
    Curr Drug Metab; 2002 Oct; 3(5):481-90. PubMed ID: 12369894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 57 varieties: the human cytochromes P450.
    Lewis DF
    Pharmacogenomics; 2004 Apr; 5(3):305-18. PubMed ID: 15102545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human cytochrome P450 monooxygenases for drug metabolite synthesis.
    Schroer K; Kittelmann M; Lütz S
    Biotechnol Bioeng; 2010 Aug; 106(5):699-706. PubMed ID: 20506361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.